Vascular disease—including narrowing and occlusion of blood vessels that deliver oxygen and nutrients to the heart, vital organs and extremities—is often a co-morbid condition in patients with high blood pressure, high cholesterol and diabetes, some of the biggest public health burdens in developed nations. Vascular disease itself inflicts a significant public health burden for which improved methodologies to model disease, develop therapeutics, and design new interventions to alleviate disease may provide symptomatic relief and improve function. The proposed study aims to overcome a major limitation in the development of patient-derived endothelial cells using induced pluripotent stem cell technology, which is the need for long-term function without degeneration of the important endothelial-like phenotype. The tools, technologies and information developed by the proposed science will ultimately provide a new inexhaustible source of patient-derived endothelial-like cells for vascular disease modeling, such as evaluating the cellular response to management of neointimal hyperplasia, or development of new patient-specific endothelial cell-lined vascular grafts with improved patency and removing the need for long-term therapeutic anticoagulation. These advances with endothelial cells may also carry implications for other cell types and potentially advance regenerative medicine work in other organ systems as well, including kidney and liver regeneration, which hold the promise of meeting a greater unmet need of transplantable organs with an on-demand supply of bioengineered organs.
|Effective start/end date||7/1/18 → 6/30/19|
- Association for Academic Surgery and the Association for Academic Surgery Foundation (AGREEMENT 3/28/18)